Department of Biomedical Engineering, University of Virginia, 415 Lane Rd., Charlottesville, VA 29908, USA.
Clin Chim Acta. 2010 Jan;411(1-2):106-13. doi: 10.1016/j.cca.2009.10.017. Epub 2009 Oct 25.
Unregulated hemostasis represents a leading cause of mortality and morbidity in the developed world. Being able to recognize and quantify defects of the hemostatic process is critical to reduce mortality and implement appropriate treatment.
We describe a novel ultrasound-based technology, named sonorheometry, which can assess hemostasis function from a small sample of blood. Sonorheometry uses the phenomenon of acoustic radiation force to measure the dynamic changes in blood viscoelasticity during clot formation and clot dissolution. We performed in vitro experiments using whole blood samples of 1 ml to demonstrate that sonorheometry is indicative of hemostatic functions that depend on plasma coagulation factors, platelets, and plasma fibrinolytic factors.
Sonorheometry measurements show titration effects to compounds known to alter the coagulation factors (GPRP peptide, 0 to 8 mmol/l), platelets (abciximab, 0 to 12 microg/ml), and fibrinolytic factors (urokinase, 0 to 200 U). Repeated measurements of blood samples from the same subjects yielded reproducibility errors on the order of 5%.
These data indicate that sonorheometry accurately quantifies the functional role of the components of hemostasis in vitro.
在发达国家，不受控制的止血是导致死亡率和发病率的主要原因。能够识别和量化止血过程的缺陷对于降低死亡率和实施适当的治疗至关重要。
我们描述了一种新型的基于超声的技术，称为声触诊组织弹性成像技术，它可以从小量血液样本中评估止血功能。声触诊组织弹性成像技术利用声辐射力的现象来测量血液在形成和溶解过程中的动态粘弹性变化。我们使用 1 毫升全血样本进行了体外实验，证明声触诊组织弹性成像技术可指示依赖于血浆凝血因子、血小板和血浆纤维蛋白溶解因子的止血功能。
声触诊组织弹性成像技术的测量结果显示，对已知改变凝血因子（GPRP 肽，0 至 8mmol/l）、血小板（阿昔单抗，0 至 12μg/ml）和纤维蛋白溶解因子（尿激酶，0 至 200U）的化合物有滴定效应。对同一受试者的血液样本进行重复测量，其重复性误差约为 5%。
这些数据表明，声触诊组织弹性成像技术可准确地定量体外止血成分的功能作用。
